Nanoparticles and the Blood-Brain Barrier: Advancing from In-Vitro Models Towards Therapeutic Significance

被引：97
作者：
Mc Carthy, David J. [1 ,2 ]
Malhotra, Meenakshi [1 ]
O'Mahony, Aoife M. [1 ]
Cryan, John F. [2 ,3 ]
O'Driscoll, Caitriona M. [1 ]
机构：
[1] Natl Univ Ireland Univ Coll Cork, Sch Pharm, Pharmacodelivery Grp, Cavanagh Pharm Bldg, Cork, Ireland
[2] Natl Univ Ireland Univ Coll Cork, Dept Anat & Neurosci, Cork, Ireland
[3] Alimentary Pharmabiot Ctr, Lab Neurogastroenterol, Cork, Ireland
来源：
PHARMACEUTICAL RESEARCH | 2015年 / 32卷 / 04期
关键词：
Blood-brain barrier; Drug delivery to the CNS; In vitro models; Targeted nanoparticles; Transcytosis; CENTRAL-NERVOUS-SYSTEM; SOLID LIPID NANOPARTICLES; ASTROCYTE-ENDOTHELIAL INTERACTIONS; BETA-CYCLODEXTRIN NANOPARTICLES; ARGININE-RICH PEPTIDES; SMALL INTERFERING RNA; DRUG-DELIVERY; PLGA NANOPARTICLES; CELLULAR UPTAKE; TAT PEPTIDE;
D O I：
10.1007/s11095-014-1545-6
中图分类号：
O6 [化学];
学科分类号：
0703 ;
摘要：
The blood-brain barrier is a unique cell-based restrictive barrier that prevents the entry of many substances, including most therapeutics, into the central nervous system. A wide range of nanoparticulate delivery systems have been investigated with the aim of targeting therapeutics (drugs, nucleic acids, proteins) to the brain following administration by various routes. This review provides a comprehensive description of the design and formulation of these nanoparticles including the rationale behind individual approaches. In addition, the ability of currently available in-vitro BBB models to accurately predict the in-vivo performance of targeted nanoparticles is critically assessed.
引用
收藏
页码：1161 / 1185
页数：25
相关论文
共 217 条
  • [1] Abbott NJ, 2012, METHODS MOL BIOL, V814, P415, DOI 10.1007/978-1-61779-452-0_28
  • [2] Structure and function of the blood-brain barrier
    Abbott, N. Joan
    Patabendige, Adjanie A. K.
    Dolman, Diana E. M.
    Yusof, Siti R.
    Begley, David J.
    [J]. NEUROBIOLOGY OF DISEASE, 2010, 37 (01) : 13 - 25
  • [3] Astrocyte-endothelial interactions at the blood-brain barrier
    Abbott, NJ
    Rönnbäck, L
    Hansson, E
    [J]. NATURE REVIEWS NEUROSCIENCE, 2006, 7 (01) : 41 - 53
  • [4] Astrocyte-endothelial interactions and blood-brain barrier permeability
    Abbott, NJ
    [J]. JOURNAL OF ANATOMY, 2002, 200 (06) : 629 - 638
  • [5] Development of a smart nano-vehicle to target cerebrovascular amyloid deposits and brain parenchymal plaques observed in Alzheimer's disease and cerebral amyloid angiopathy
    Agyare, Edward K.
    Curran, Geoffry L.
    Ramakrishnan, Muthu
    Yu, Caroline C.
    Poduslo, Joseph F.
    Kandimalla, Karunya K.
    [J]. PHARMACEUTICAL RESEARCH, 2008, 25 (11) : 2674 - 2684
  • [6] Development and brain delivery of chitosan-PEG nanoparticles functionalized with the monoclonal antibody OX26
    Aktas, Y
    Yemisci, M
    Andrieux, K
    Gürsoy, RN
    Alonso, MJ
    Fernandez-Megia, E
    Novoa-Carballal, R
    Quiñoá, E
    Riguera, R
    Sargon, MF
    Çelik, HH
    Demir, AS
    Hincal, AA
    Dalkara, T
    Çapan, Y
    Couvreur, P
    [J]. BIOCONJUGATE CHEMISTRY, 2005, 16 (06) : 1503 - 1511
  • [7] In Vivo Distribution and Toxicity of PAMAM Dendrimers in the Central Nervous System Depend on Their Surface Chemistry
    Albertazzi, Lorenzo
    Gherardini, Lisa
    Brondi, Marco
    Sato, Sebastian Sulis
    Bifone, Angelo
    Pizzorusso, Tommaso
    Ratto, Gian Michele
    Bardi, Giuseppe
    [J]. MOLECULAR PHARMACEUTICS, 2013, 10 (01) : 249 - 260
  • [8] ALYAUTDIN R, 1995, EUR J PHARM BIOPHARM, V41, P44
  • [9] Alzheimers Disease International & World Health Organization, 2015, Dementia: a public health priority, ISBN
  • [10] Body distribution of polysorbate-80 and doxorubicin-loaded [14C]poly(butyl cyanoacrylate) nanoparticles after i.v. administration in rats
    Ambruosi, A
    Yamamoto, H
    Kreuter, J
    [J]. JOURNAL OF DRUG TARGETING, 2005, 13 (10) : 535 - 542
12345678910